PML: The Dark Side of Immunotherapy in Multiple Sclerosis

Trends in Pharmacological Sciences

Volumn 36, Issue 12, 2015, Pages 799-801

  Warnke, Clemens ^a   Olsson, Tomas ^b   Hartung, Hans Peter ^a  

^a Department of Orthopedic Surgery   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

JC virus; natalizumab; PML; risk

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MITOXANTRONE; NATALIZUMAB; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TERIFLUNOMIDE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INCIDENCE; JC VIRUS; MULTIPLE SCLEROSIS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK FACTOR; TREATMENT DURATION; VIRUS MUTATION; VIRUS REPLICATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; FINGOLIMOD HYDROCHLORIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; NATALIZUMAB;

EID: 84949500653     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.09.006     Document Type: Short Survey

References (16)

1. J. Burman, and et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience J. Neurol. Neurosurg. Psychiatry 85 2014 1116 1121
2. C. Warnke, and et al. Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards J. Neural Transm. 120 Suppl. 1 2013 S55 S60
3. T.A. Yednock, and et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356 1992 63 66
4. T. Bartsch, and et al. Progressive hemiparesis in a psoriasis patient treated with dimethyl fumarate Ann. Neurol. 2015 (in press)
5. K.R. Carson, and et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Blood 113 2009 4834 4840
6. J. Van Schependom, and et al. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail Mult. Scler. 2015 (in press)
7. T. Olsson, and et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort Mult. Scler. 19 2013 1533 1538
8. C. Warnke, and et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch. Neurol. 67 2010 923 930
9. C. Warnke, and et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis Neurology 15 2013 1400 1408
10. C. Warnke, and et al. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF Mult. Scler. 21 2015 1036 1044
11. E.O. Major, and et al. JC viremia in natalizumab-treated patients with multiple sclerosis N. Engl. J. Med. 6 2013 2240 2241
12. E. Sundqvist, and et al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants PLoS Pathog. 10 2014 e1004084
13. T. Plavina, and et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy Ann. Neurol. 76 2014 802 812
14. J.R. Berger, and et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section Neurology 80 2013 1430 1438
15. M.P. Wattjes, and et al. MRI pattern in asymptomatic natalizumab-associated PML J. Neurol. Neurosurg. Psychiatry 86 2015 793 798
16. C. Warnke, and et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy Ann. Neurol. 76 2014 792 801